Health Secretary Robert F. Kennedy Jr. has indicated he plans to expand public access to approximately 14 injectable peptide drugs that are currently restricted by federal regulators.

The Food and Drug Administration restricted 17 peptides in 2023, citing "potential significant safety risks." These compounds have not been proven safe or effective for human use through clinical trials. Peptides are molecules that serve various functions in the human body, including cell signaling, and encompass a wide range of substances with different properties and potential effects.

Kennedy's proposal aligns with his broader "Make America Healthy Again" agenda, which emphasizes reducing regulatory restrictions on health products and expanding individual choice in medical decisions. This approach contrasts with traditional regulatory frameworks that require extensive safety and efficacy testing before approving drugs for public use.

The peptide category includes both beneficial compounds, such as certain weight-loss medications currently approved for medical use, as well as potentially harmful substances. Each peptide requires separate evaluation for safety and therapeutic value.

The proposal represents part of a broader shift in health policy direction under Kennedy's leadership, which has signaled intentions to reduce federal oversight of various health products and interventions while emphasizing personal choice in medical decisions.